Michael Fried
University of North Carolina, USA
Michael W. Fried, MD is Professor of Medicine and Director of Hepatology at the University of North Carolina (UNC) at Chapel Hill. He is currently President of the American Association for the Study of Liver Diseases (AASLD). Dr. Fried received his medical degree from Tel Aviv University, and completed training in Internal Medicine and Gastroenterology at the State University of New York Health Science Center at Syracuse.
From 1990 to 1993, while serving as Medical Staff Fellow at the National Institutes of Health (NIH), Dr. Fried performed clinical and laboratory studies of viral hepatitis. He has been principal investigator on numerous clinical trials of antiviral agents for hepatitis B and hepatitis C that defined treatment paradigms for these diseases. Dr. Fried has been awarded continuous NIH extramural funding for over 20 years as principal investigator on several NIH cooperative clinical trials and he currently serves as the co-chair of the NIH Hepatitis B Research Network. He is also co-principal investigator of the HCV-TARGET international network studying HCV therapies used in usual clinical practice. Dr. Fried and the HCV-TARGET team were recently awarded the FDA Excellence in Regulatory Science Award for their contributions to optimizing management for patients with hepatitis C.
Dr. Fried is the primary author or co-author of over 200 original publications, reviews, and book chapters. He is also the co-Founder and Scientific Advisor for TARGET PharmaSolutions.